🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Sickle Cells Patients

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease NCT06385886n/a9 sites📍 Birmingham📍 Phoenix📍 Oakland RTI International · Tests: Linkage Coordinator A Long-term Follow-up Study in Patients Who Received BEAM-101 NCT07373639n/a17 sites📍 Birmingham📍 Phoenix📍 Jacksonville Beam Therapeutics Inc. · Tests: Long-Term Follow-up Study of patients who received BEAM-101 Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease NCT06941389n/a37 sites📍 Birmingham📍 Birmingham📍 Wilmington University of Rochester CS-206 in Patients With Sickle Cell Disease NCT06565026EARLY Phase 11 site📍 Nanning CorrectSequence Therapeutics Co., Ltd · Tests: CS-206 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease NCT06944067n/a1 site📍 Bethesda National Human Genome Research Institute (NHGRI) Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET NCT05583721Phase 21 site📍 Memphis St. Jude Children's Research Hospital · Tests: [13N]NH3, Lexiscan, Positron emission tomography Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease NCT02675959Phase 24 sites📍 Los Angeles📍 Gainesville📍 Valhalla New York Medical College · Tests: Defibrotide Study of Vitamin B12 Metabolism in Children With Sickle Cell Disease Exposed to MEOPA NCT06581900n/a1 site📍 Reims CHU de Reims · Tests: Vitamin B12 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) NCT07015684Phase 11 site📍 New York Columbia University · Tests: 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease NCT07316478NA1 site📍 Philadelphia University of Pennsylvania · Tests: Stress Management and Mindfulness Intervention for Patients with Sickle Cell Disease Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease NCT04774536Phase 1, Phase 23 sites📍 Davis📍 Los Angeles📍 Oakland Mark Walters, MD · Tests: CRISPR_SCD001 Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease NCT06635902Phase 21 site📍 Washington D.C. Suvankar Majumdar · Tests: L-citrulline, Placebo, L-citrulline Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody NCT06358638Phase 21 site📍 Washington D.C. Children's National Research Institute · Tests: Daratumumab, Alemtuzumab, Sirolimus, Total Body Irradiation Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease NCT03353584NA2 sites📍 Memphis📍 Memphis St. Jude Children's Research Hospital · Tests: Virtual Reality Therapy Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease NCT06919224NA4 sites📍 Chicago📍 St Louis📍 Columbus Ohio State University · Tests: mHealth app + booklets Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease NCT03685721n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease NCT01245179Phase 11 site📍 Augusta Abdullah Kutlar · Tests: panobinostat Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia NCT06761560Phase 2, Phase 31 site📍 Montreal Yves Pastore · Tests: Pharmacokinetic based dosage change, Pharmacokinetic dosing Hydroxyurea Optimisation in Sickle Cell Disease NCT07543289n/a1 site📍 Ile-Ife Ochuko Orherhe · Tests: Hydroxyurea (HU) Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC NCT04528355n/a1 site📍 Pittsburgh Paul Szabolcs · Tests: data collection Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease NCT06818266Phase 31 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) NCT06439082Phase 336 sites📍 Birmingham📍 Orange📍 Washington D.C. Novartis Pharmaceuticals · Tests: Crizanlizumab, Placebo Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain NCT06773715NA1 site📍 New Orleans Louisiana State University Health Sciences Center in New Or… · Tests: KindVR Aqua Program T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias NCT03653338Phase 1, Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab RH Genotype Matched RBC Transfusions NCT04156893Phase 1, Phase 21 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Red cell units that are genotype matched at the RHD and RHCE loci Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient NCT06887907n/a1 site📍 Toulouse University Hospital, Toulouse RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs) NCT06213402n/a1 site📍 Barcelona Hospital Universitari Vall d'Hebron Research Institute · Tests: Data collection from EHR. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease NCT06546670Phase 1, Phase 214 sites📍 Birmingham📍 Miami📍 Boston Novartis Pharmaceuticals · Tests: ITU512, Placebo Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease NCT07252050Phase 1, Phase 24 sites📍 Aurora📍 Atlanta📍 New Orleans Arkansas Children's Hospital Research Institute · Tests: Ruxolitinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy